ORR BY HISTOLOGY
IN THE PHASE III ABRAXANE STUDY

ORR BY HISTOLOGY
IN THE PHASE III ABRAXANE STUDY

Squamous advanced NSCLC
Squamous advanced NSCLC

Squamous Advanced Non-Small Cell Lung Cancer (NSCLC) overall response rate by histology - chart Squamous Advanced Non-Small Cell Lung Cancer (NSCLC) overall response rate by histology - chart

Over 1000 first-line patients with aNSCLC
  • In the ABRAXANE + carboplatin arm:
    44% had squamous histology (n=229/521)
    56% had nonsquamous histology (n=292/521)
Nonsquamous advanced NSCLC (ORR)
  • Carcinoma/adenocarcinoma:
    26% (66/254) for ABRAXANE + carboplatin vs
    27% (71/264) for paclitaxel injection + carboplatin
  • Large cell carcinoma:
    33% (3/9) for ABRAXANE + carboplatin vs
    15% (2/13) for paclitaxel injection + carboplatin
  • Other forms of nonsquamous disease:
    24% (7/29) for ABRAXANE + carboplatin vs
    15% (5/33) for paclitaxel injection + carboplatin
Over 1000 first-line patients with aNSCLC
  • In the ABRAXANE + carboplatin arm:
    44% had squamous histology (n=229/521)
    56% had nonsquamous histology (n=292/521)
Nonsquamous advanced NSCLC (ORR)
  • Carcinoma/adenocarcinoma:
    26% (66/254) for ABRAXANE + carboplatin vs
    27% (71/264) for paclitaxel injection + carboplatin
  • Large cell carcinoma:
    33% (3/9) for ABRAXANE + carboplatin vs
    15% (2/13) for paclitaxel injection + carboplatin
  • Other forms of nonsquamous disease:
    24% (7/29) for ABRAXANE + carboplatin vs
    15% (5/33) for paclitaxel injection + carboplatin
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL